Mazindol Multi-Reuptake Modulation for CNS Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for CNS disorders such as major depressive disorder, generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive compulsive disorder, autism, aggression, intermittent explosive disorder, attachment disorder, attention deficit hyperactivity disorder, and schizophrenia often have significant side effects and do not effectively leverage the μ-opioid receptor agonist activity of mazindol.
Innovation Solution
A method of treatment using mazindol, which exhibits noradrenergic (NRI), serotonergic (SRI), and dopaminergic reuptake transporter inhibitory (DRI) activity, combined with μ-opioid receptor agonist activity, is administered to address these disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for CNS disorders are used, then therapeutic effect is achieved, but significant side effects occur
Solution Approach 1:
The patent changes the pharmacological parameters by selecting mazindol, which has a unique combination of reuptake inhibitor activity and μ-opioid receptor agonist activity, differing from conventional single-mechanism treatments. This dual-mechanism parameter change provides therapeutic efficacy while reducing side effects through balanced receptor engagement
Solution Approach 2:
Mazindol serves multiple functions simultaneously: it acts as a noradrenergic reuptake inhibitor, serotonergic reuptake inhibitor, dopaminergic reuptake inhibitor, and μ-opioid receptor agonist. This multi-functionality allows a single agent to address multiple neurotransmitter systems involved in CNS disorders, improving therapeutic reliability while minimizing the need for polypharmacy and associated side effects
2Productivity
If conventional treatments targeting single neurotransmitter systems are used, then specific symptom relief is achieved, but overall efficacy is limited
Solution Approach 1:
The patent merges multiple neurotransmitter modulation mechanisms into a single therapeutic agent. Mazindol combines noradrenergic, serotonergic, and dopaminergic reuptake inhibition with μ-opioid receptor agonism, creating a synergistic effect that addresses the complex pathophysiology of CNS disorders more comprehensively than single-mechanism treatments
Solution Approach 2:
By engaging multiple neurotransmitter systems simultaneously, mazindol provides universal coverage for diverse symptoms associated with CNS disorders. This multi-functional approach ensures both specific symptom relief and comprehensive overall efficacy, overcoming the limitations of conventional monotherapy
Data Source
AI summary
The invention comprises a method of treatment of CNS disorders by a pharmaceutical agent exhibiting combined noradrenergic, serotonergic or dopaminergic reuptake transporter inhibitory and μ-opioid agonistic activity.